← All trials
NCT06214468
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 15, 2024
- Primary completion
- Jun 15, 2024
- Completion date
- Apr 30, 2025
- First posted
- Jan 19, 2024
- Last posted
- Jan 19, 2024
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of South AlabamaLead sponsor
- University of South AlabamaOfficial
- NASACollaborator
- University of Alabama, BirminghamCollaborator
- University of South AlabamaSponsor investigator
- Rutgers UniversityCollaborator
- University of Nevada, Las VegasCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.